10-Q: Vitro BioPharma Reports Q2 2026 Financials, Faces Going Concern Doubt

Vitro BioPharma, Inc. filed its Form 10-Q for the quarter ended April 30, 2026, detailing a net loss of $1.55 million and highlighting substantial doubt about its ability to continue as a going concern.

Summary

• Vitro BioPharma, Inc. reported a net loss of $1,553,225 for the three months ended April 30, 2026, an increase of 5% from the prior year's quarter.
• Total revenue for the quarter decreased by 13% to $446,295, primarily due to a significant drop in AlloRx Stem Cell sales to foreign third-party clinics.
• InfiniVive product sales saw a substantial increase of 701% to $179,718.
• Selling, General, and Administrative (SG&A) expenses increased by 14% to $1,404,747, driven by higher salaries and consulting fees.
• Research and Development (R&D) expenses decreased by 51% to $109,806.
• The company has a working capital deficit of approximately $16.3 million as of April 30, 2026, and has incurred net losses, raising substantial doubt about its ability to continue as a going concern.
• Management plans to address the going concern issue by raising additional capital through equity or debt offerings and pursuing revenue generation initiatives.
• Subsequent to the quarter, a significant capital raise of $7.3 million in Series A-1 Preferred Stock triggered conversions of outstanding notes, leading to the issuance of 837,273 shares of Series A-1 Preferred Stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, decreased revenue, and significant going concern doubts, despite some positive product sales growth in specific segments.

Positives

• InfiniVive product sales increased significantly by 701% to $179,718 for the three months ended April 30, 2026.
• Research and development product sales increased by 35% to $164,797 for the three months ended April 30, 2026, driven by increased purchases of CAFs and native fibroblasts.
• Gross profit margin improved slightly to 77% for the three months ended April 30, 2026, from 74% in the prior year period.
• Net loss for the six months ended April 30, 2026, decreased by 38% to $2,660,193 compared to the same period in 2025.
• Subsequent to the quarter end, the company raised $7.3 million in Series A-1 Preferred Stock, triggering conversions of debt and increasing the Series A-1 Preferred Stock outstanding.

Negatives

• The company reported a net loss of $1,553,225 for the three months ended April 30, 2026, an increase of 5% from the prior year.
• Total revenue decreased by 13% to $446,295 for the three months ended April 30, 2026.
• Sales of AlloRx Stem Cells to foreign third-party clinics decreased significantly by 72% to $101,780.
• SG&A expenses increased by 14% to $1,404,747.
• The company has a substantial working capital deficit of $16.3 million as of April 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern.
• A loss on extinguishment of debt of $312,550 was recorded in the three months ended April 30, 2026.
• Impairment expense of $99,700 was recorded for the six months ended April 30, 2026, due to a failed production batch of AlloRx.

Risks

• The company has incurred significant operating losses and expects to continue doing so, raising substantial doubt about its ability to continue as a going concern.
• The company's current cash position is insufficient to support daily operations for the next 12 months.
• Failure to raise additional capital through debt or equity financings could lead to delays, reductions, or termination of drug development efforts.
• The company is dependent on future capital raises, which are not guaranteed to be successful.
• Sales of AlloRx Stem Cells to foreign third-party clinics have decreased significantly, and future increases are dependent on market recovery and expansion.
• The company's ability to commence clinical trials for AlloRx Stem Cell therapy is contingent on obtaining sufficient working capital, estimated at $4 million to $6 million.
• The company faces risks related to the development and commercialization of its product candidates, including regulatory approval, market acceptance, and competition.

Future Outlook

The company expects to continue reporting losses until it can improve operations and/or commercialize its product candidates to generate sufficient sales to offset operating and interest expenses. The company anticipates increased SG&A expenses due to growth and public company costs, and significantly increased R&D expenses as clinical trials commence. Future funding requirements are substantial and depend on clinical trial progress, regulatory approvals, and market conditions.

Management Comments

• We expect to continue reporting losses until such time, if ever, we can improve the operation of our subsidiaries and/or commercialize one or more of our product candidates and generate sales sufficient to offset our operating costs and expenses and interest expenses.
• We expect AlloRx Stem Cell sales internationally to increase over the next year as these products expand into additional foreign third-party clinics and medical centers and our current foreign third-party clinics and medical center customers increase their total monthly patients as international travel continues to pick back up.
• We expect InfiniVive product sales domestically and internationally to increase over the next year as these products expand into additional foreign and domestic third-party clinics and med spas.
• In order to continue as a going concern, as well as to meet our operational goals, we will need to obtain additional capital in both the short and long term, which we will likely obtain through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations.

Industry Context

StockSavvy.ai notes that Vitro BioPharma operates in the highly competitive and capital-intensive biotechnology sector, where significant investment in research and development is required to bring novel therapies to market. The company's focus on stem cell therapies for autoimmune and inflammatory diseases aligns with growing industry interest in regenerative medicine, but faces challenges common to early-stage biotechs, including long development cycles, high failure rates, and the need for substantial funding.

Comparison to Industry Standards

• The company's net loss of $1.55 million for the quarter and $2.66 million for the six months is substantial for its revenue base, which is typical for early-stage biotechnology companies investing heavily in R&D.
• The significant increase in InfiniVive product sales (701%) is a positive indicator of market acceptance for its cosmeceutical line, though it represents a smaller portion of overall revenue compared to AlloRx.
• The decrease in AlloRx Stem Cell sales is a concern, especially given the company's stated expectation for future increases, which may be challenged by broader market dynamics or competitive pressures affecting international clinics.
• The company's reliance on external financing to fund operations and clinical trials is a standard practice in the biotech industry, but the 'substantial doubt about going concern' highlights a critical liquidity challenge that needs to be addressed proactively.

Legal Proceedings

• No legal proceedings, government actions, administrative actions, investigations, or claims are currently pending or threatened against the company or its officers and directors, except as may be set forth in the Form 10-K filed on February 13, 2026.

Related Party Transactions

• Sales to Dr. Jack Zamora (former CEO and 29% stockholder) accounted for $0 in product sales for the three months ended April 30, 2026, and $0 for the six months ended April 30, 2026.
• The spouse of the Chief Science Officer leases office and lab space to the company.
• As of April 30, 2026, the company owed $22,610 in travel expense reimbursements and $970,000 in accrued, unpaid bonuses to the CEO.

Stakeholder Impact

• Shareholders face dilution risk from potential future equity financings and the ongoing net losses impacting stock value.
• Creditors and noteholders are exposed to the company's going concern risk, although recent capital raises and debt conversions are positive developments.
• Employees may face uncertainty due to the company's financial position and potential need for operational adjustments.
• Customers of AlloRx Stem Cells may experience continued reduced supply or availability if sales do not recover as anticipated.

Next Steps

• Commence clinical trials for AlloRx Stem Cell therapy in PTHS and Long COVID, pending sufficient working capital.
• Expand InfiniVive product sales domestically and internationally.
• Increase AlloRx Stem Cell sales internationally as products expand into additional foreign clinics.
• Continue efforts to prepare AlloRx Stem Cell therapy and regenerative aesthetics products for future clinical trials.
• Pursue additional capital through debt or equity financings.

Key Dates

Recommendation

The company's significant financial challenges, including a going concern warning and increased net loss, are concerning. However, the recent capital infusion and subsequent debt conversions, along with positive growth in InfiniVive sales, suggest potential for recovery. Investors should hold positions while monitoring the company's ability to secure further funding and execute its clinical development plans.

Keywords

Vitro BioPharma, 10-Q, Quarterly Report, Biotechnology, Stem Cells, AlloRx, InfiniVive, Financial Results, Going Concern, Clinical Trials, SEC Filing